About this Journal Submit a Manuscript Table of Contents
BioMed Research International
Volume 2013 (2013), Article ID 976765, 7 pages
http://dx.doi.org/10.1155/2013/976765
Research Article

Loss of RASSF1A Expression in Colorectal Cancer and Its Association with K-ras Status

1Department of Medical Oncology, Cancer Center, The State Key Laboratory of Biotherapy, West China Hospital, West China Medical School, Sichuan University, 37 Guo Xue Xiang, Chengdu, Sichuan 610041, China
2Department of Pathology, West China Hospital, West China Medical School, Sichuan University, Chengdu 610041, China

Received 6 April 2013; Accepted 29 May 2013

Academic Editor: Renfu Shao

Copyright © 2013 Dan Cao et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. J. Y. Fang and B. C. Richardson, “The MAPK signalling pathways and colorectal cancer,” The Lancet Oncology, vol. 6, no. 5, pp. 322–327, 2005. View at Publisher · View at Google Scholar · View at Scopus
  2. T. Ahlquist, I. Bottillo, S. A. Danielsen et al., “RAS signaling in colorectal carcinomas through alterations of RAS, RAF, NF1, and/or RASSF1A,” Neoplasia, vol. 10, no. 7, pp. 680–686, 2008. View at Publisher · View at Google Scholar · View at Scopus
  3. E. Santos, D. Martin Zanca, and E. P. Reddy, “Malignant activation of a K-ras oncogene in lung carcinoma but not in normal tissue of the same patient,” Science, vol. 223, no. 4637, pp. 661–664, 1984. View at Scopus
  4. S. Salerno, V. Bazan, R. M. Tomasino et al., “Specific codon 13 K-ras mutations are predictive of clinical outcome in colorectal cancer patients, whereas codon 12 K-ras mutations are associated with mucinous histotype,” Annals of Oncology, vol. 13, no. 9, pp. 1438–1446, 2002. View at Publisher · View at Google Scholar · View at Scopus
  5. S. Ogino, K. Nosho, G. J. Kirkner et al., “CpG island methylator phenotype, microsatellite instability, BRAF mutation and clinical outcome in colon cancer,” Gut, vol. 58, no. 1, pp. 90–96, 2009. View at Publisher · View at Google Scholar · View at Scopus
  6. G. P. Pfeifer and R. Dammann, “Methylation of the tumor suppressor gene RASSF1A in human tumors,” Biochemistry, vol. 70, no. 5, pp. 576–583, 2005. View at Publisher · View at Google Scholar · View at Scopus
  7. L. B. Hesson, W. N. Cooper, and F. Latif, “The role of RASSF1A methylation in cancer,” Disease Markers, vol. 23, no. 1-2, pp. 73–87, 2007. View at Scopus
  8. S. H. Park, J. J. Kim, J. S. Chung et al., “RASSF1A suppresses the activated K-Ras-induced oxidative DNA damage,” Biochemical and Biophysical Research Communications, vol. 408, no. 1, pp. 149–153, 2011. View at Publisher · View at Google Scholar · View at Scopus
  9. H. Donninger, M. D. Vos, and G. J. Clark, “The RASSF1A tumor suppressor,” Journal of Cell Science, vol. 120, no. 18, pp. 3163–3172, 2007. View at Publisher · View at Google Scholar · View at Scopus
  10. D. G. Burbee, E. Forgacs, S. Zöchbauer-Müller et al., “Epigenetic inactivation of RASSF1A in lung and breast cancers and malignant phenotype suppression,” Journal of the National Cancer Institute, vol. 93, no. 9, pp. 691–699, 2001. View at Scopus
  11. I. Kuzmin, J. W. Gillespie, A. Protopopov et al., “The RASSF1A tumor suppressor gene is inactivated in prostate tumors and suppresses growth of prostate carcinoma cells,” Cancer Research, vol. 62, no. 12, pp. 3498–3502, 2002. View at Scopus
  12. T. Wang, H. Liu, Y. Chen, W. Liu, J. Yu, and G. Wu, “Methylation associated inactivation of RASSF1A and its synergistic effect with activated K-Ras in nasopharyngeal carcinoma,” Journal of Experimental and Clinical Cancer Research, vol. 28, no. 1, article 160, 2009. View at Publisher · View at Google Scholar · View at Scopus
  13. R. Bhagat, S. Chadaga, C. S. Premalata, et al., “Aberrant promoter methylation of the RASSF1A and APC genes in epithelial ovarian carcinoma development,” Cellular Oncology, vol. 35, no. 6, pp. 473–479, 2012.
  14. H. Chen, M. Suzuki, Y. Nakamura et al., “Aberrant methylation of RASGRF2 and RASSF1A in human non-small cell lung cancer,” Oncology Reports, vol. 15, no. 5, pp. 1281–1285, 2006. View at Scopus
  15. S. K. Kee, J. Y. Lee, M. J. Kim et al., “Hypermethylation of the Ras association domain family 1A (RASSF1A) gene in gallbladder cancer,” Molecules and Cells, vol. 24, no. 3, pp. 364–371, 2007. View at Scopus
  16. P. H. Y. Lo, D. Xie, K. C. Chan et al., “Reduced expression of RASSF1A in esophageal and nasopharyngeal carcinomas significantly correlates with tumor stage,” Cancer Letters, vol. 257, no. 2, pp. 199–205, 2007. View at Publisher · View at Google Scholar · View at Scopus
  17. M.-G. Lee, H.-Y. Kim, D.-S. Byun et al., “Frequent epigenetic inactivation of RASSF1A in human bladder carcinoma,” Cancer Research, vol. 61, no. 18, pp. 6688–6692, 2001. View at Scopus
  18. M. D. Vos, C. A. Ellis, A. Bell, M. J. Birrer, and G. J. Clark, “Ras uses the novel tumor suppressor RASSF1 as an effector to mediate apoptosis,” Journal of Biological Chemistry, vol. 275, no. 46, pp. 35669–35672, 2000. View at Publisher · View at Google Scholar · View at Scopus
  19. W. Yeo, W.-L. Wong, N. Wong, B. K. Law, G. M. Tse, and S. Zhong, “High frequency of promoter hypermethylation of RASSF1A in tumorous and non-tumourous tissue of breast cancer,” Pathology, vol. 37, no. 2, pp. 125–130, 2005. View at Publisher · View at Google Scholar · View at Scopus
  20. D.-H. Kim, J. S. Kim, J.-H. Park et al., “Relationship of Ras association domain family 1 methylation and K-Ras mutation in primary non-small cell lung cancer,” Cancer Research, vol. 63, no. 19, pp. 6206–6211, 2003. View at Scopus
  21. B. Gao, X.-J. Xie, C. Huang et al., “RASSF1A polymorphism A133S is associated with early onset breast cancer in BRCA1/2 mutation carriers,” Cancer Research, vol. 68, no. 1, pp. 22–25, 2008. View at Publisher · View at Google Scholar · View at Scopus
  22. J. M. A. Pijnenborg, G. C. Dam-de Veen, N. Kisters et al., “RASSF1A methylation and K-ras and B-raf mutations and recurrent endometrial cancer,” Annals of Oncology, vol. 18, no. 3, pp. 491–497, 2007. View at Publisher · View at Google Scholar · View at Scopus
  23. E. Azizi, A. Kittai, and P. Kozuch, “Antiepidermal growth factor receptor monoclonal antibodies: applications in colorectal cancer,” Chemotherapy Research and Practice, vol. 2012, Article ID 198197, 15 pages, 2012. View at Publisher · View at Google Scholar
  24. X. Cui, Y. Shirai, T. Wakai, N. Yokoyama, S. Hirano, and K. Hatakeyama, “Aberrant expression of pRb and p16INK4a, alone or in combination, indicates poor outcome after resection in patients with colorectal carcinoma,” Human Pathology, vol. 35, no. 10, pp. 1189–1195, 2004. View at Publisher · View at Google Scholar · View at Scopus
  25. N. S. Goldstein and M. Armin, “Epidermal growth factor receptor immunohistochemical reactivity in patients with American Joint Committee on Cancer Stage IV colon adenocarcinoma: implications for a standardized scoring system,” Cancer, vol. 92, no. 5, pp. 1331–1346, 2001.
  26. X. Cui, T. Wakai, Y. Shirai, K. Hatakeyama, and S. Hirano, “Chronic oral exposure to inorganic arsenate interferes with methylation status of p16INK4a and RASSF1A and induces lung cancer in A/J mice,” Toxicological Sciences, vol. 91, no. 2, pp. 372–381, 2006. View at Publisher · View at Google Scholar · View at Scopus
  27. E. Miranda, A. Destro, A. Malesci et al., “Genetic and epigenetic changes in primary metastatic and nonmetastatic colorectal cancer,” British Journal of Cancer, vol. 95, no. 8, pp. 1101–1107, 2006. View at Publisher · View at Google Scholar · View at Scopus
  28. G. Poulogiannis, F. Luo, and M. J. Arends, “RAS signalling in the colorectum in health and disease,” Cell Communication and Adhesion, vol. 19, no. 1, pp. 1–9, 2012. View at Publisher · View at Google Scholar · View at Scopus
  29. M. Spugnardi, S. Tommasi, R. Dammann, G. P. Pfeifer, and D. S. B. Hoon, “Epigenetic inactivation of RAS association domain family protein 1 (RASSF1A) in malignant cutaneous melanoma,” Cancer Research, vol. 63, no. 7, pp. 1639–1643, 2003. View at Scopus
  30. S. J. Cohen, R. B. Cohen, and N. J. Meropol, “Targeting signal transduction pathways in colorectal cancer: more than skin deep,” Journal of Clinical Oncology, vol. 23, no. 23, pp. 5374–5385, 2005. View at Publisher · View at Google Scholar · View at Scopus
  31. N. Yanagawa, G. Tamura, H. Oizumi, M. Endoh, M. Sadahiro, and T. Motoyama, “Inverse correlation between EGFR mutation and FHIT, RASSFlA and RUNX3 methylation in lung adenocarcinoma: relation with smoking status,” Anticancer Research, vol. 31, no. 4, pp. 1211–1214, 2011. View at Scopus